Cargando…

Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy

Acute myeloid leukemia (AML) is a hematological malignancy that predominantly affects the elderly. Prognosis declines with age. For those who cannot tolerate intensive chemotherapy, historically established treatment options have been hypomethylating agents (HMAs), low dose cytarabine (LDAC), and be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sanford, David, Desjardins, Pierre, Leber, Brian, Paulson, Kristjan, Assouline, Sarit, Lembo, Paola M. C., Fournier, Pierre-André, Leitch, Heather A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600019/ https://www.ncbi.nlm.nih.gov/pubmed/36290812 http://dx.doi.org/10.3390/curroncol29100535

Ejemplares similares

PB1886: REAL WORLD EXPERIENCE OF VENETOCLAX-AZACYTIDINE COMBINATION IN FRAIL ELDERLY PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY
por: Rahimi, Muhammad Naim Bin Che, et al.
Publicado: (2023)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
por: Shukla, Deepak Kumar, et al.
Publicado: (2021)

Time-dependent treatment effects of metronomic chemotherapy in unfit AML patients: a secondary analysis of a randomised controlled trial
por: Phinyo, Phichayut, et al.
Publicado: (2021)

PB1860: HIGH EFFICACY OF HYPOMETHYLATING AGENTS PLUS VENETOCLAX COMBINATION THERAPY IN ELDERLY PATIENTS AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY: A REAL-LIFE EXPERIENCE.
por: Zannier, Maria Elena, et al.
Publicado: (2023)

The Unfit
por: Sinclair, W. J. H.
Publicado: (1911)

The Unfit
Publicado: (1911)

All‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with NPM1‐mutated AML unfit for intensive chemotherapy and review of the literature
por: Forghieri, Fabio, et al.
Publicado: (2016)

PB1905: REAL-WORLD EXPERIENCE OF LOW-DOSE VENETOCLAX WITH AZACITIDINE FOR UNFIT AML PATIENTS(≥60Y) WITH LOW LEUKOCYTE COUNT
por: Wei, Wenjian, et al.
Publicado: (2023)

The Marriage of the Unfit
Publicado: (1898)

The Sterilsation of the Unfit
Publicado: (1913)

Sterilization of the Unfit
por: Bristowe, H. C.
Publicado: (1931)

National "Unfits"
Publicado: (1920)

Multiplication of the Unfit
Publicado: (1921)

Asexualization of the Unfit
Publicado: (1912)

The Marriage of the Unfit
por: Campbell, Harry
Publicado: (1898)

Sterilization of the Unfit
por: Bogart, G. Henri
Publicado: (1912)

Sterilizing the Unfit
por: Bogart, G. Henri
Publicado: (1912)

Sterilization of the Unfit
por: Bogart, G. Henri
Publicado: (1910)

Asexualization of the Unfit
Publicado: (1912)

Sterilizing the Unfit
por: Bogart, G. Henri
Publicado: (1913)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML
por: Chen, Xiaotong, et al.
Publicado: (2023)

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
por: Loschi, Michael, et al.
Publicado: (2021)

Helical tomotherapy for asymptomatic chemotherapy-refractory or -unfit multiple (3 or more) metastases
por: Yamada, Yuki, et al.
Publicado: (2022)

Making the Unfit into Serviceable Recruits
Publicado: (1916)

The Survival of the Unfit in Human Dentition
por: Parker, J. C.
Publicado: (1889)

Safeguarding Society from the Unfit
por: Cooke, A. B.
Publicado: (1911)

Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy
por: Shin, Seung-Hwan, et al.
Publicado: (2017)

P550: INFLUENCE OF RACE ON COMPLICATIONS OF INTENSIVE CHEMOTHERAPY IN AML
por: Abraham, Ivy, et al.
Publicado: (2023)

Prevalence of patients with epilepsy unfit to drive
por: Al Zaid, Esra' H.
Publicado: (2019)

HOW TO TREAT UNFIT AND FRAIL PATIENTS
por: Cook, Gordon
Publicado: (2022)

Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2019)

Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient
por: Nielsen, Torsten H., et al.
Publicado: (2013)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology
por: Zhigarev, Dmitry, et al.
Publicado: (2022)

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy
por: Abbas, Hussein A., et al.
Publicado: (2022)

Urothelial carcinoma management in elderly or unfit patients()
por: Bellmunt, Joaquim, et al.
Publicado: (2016)

Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study
por: Gangneux, Jean-Pierre, et al.
Publicado: (2020)

Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia
por: Pileckyte, Regina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lvi3shhqbr4bf9qkihs6ujefo6